Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) Bitcoin USD
68,833.76 +1,437.80 (+2.13%) CMC Crypto 200
1,390.12 +59.51 (+4.47%)
Roche Holding AG (ROG.SW)
| Previous close | 277.50 |
| Open | 280.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 278.70 - 286.40 |
| 52-week range | 212.90 - 286.40 |
| Volume | |
| Avg. volume | 1,325,495 |
| Market cap | 230.656B |
| Beta (5Y monthly) | 0.13 |
| PE ratio (TTM) | 20.00 |
| EPS (TTM) | 14.30 |
| Earnings date | 25 Jul 2024 |
| Forward dividend & yield | 9.60 (3.36%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | 269.74 |
ZacksRoche (RHHBY) Sales, Earnings Grow in 1H24, '24 EPS View Raised
Roche (RHHBY) records impressive second-quarter and first-half 2024 performance on the back of strong demand for drugs and tests. Consequently, the company raises its annual earnings guidance.
ReutersRoche lifts 2024 profit guidance on strong drug sales
FRANKFURT (Reuters) -Roche on Thursday raised its full-year earnings forecast after exceeding expectations for the first half, driven by strong demand for newer drugs such as eye medicine Vabysmo. The Swiss drugmaker said it expects growth in adjusted earnings in the "high single-digit range", excluding the effect of currency swings and resolution of tax disputes in 2023, up from previous estimates of "mid single-digit" percentage growth. First-half adjusted operating profit gained 4% to 11.3 billion Swiss francs ($12.8 billion), the family-controlled drugmaker said on Thursday, beating analysts' consensus estimate of 10.5 billion, based on LSEG data.
GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised
Group sales were up by 5%1 at constant exchange rates (CER) (stable in CHF) in the first half, driven by the high demand for both our medicines and diagnostics; excluding COVID-19-related products, sales increased by 8% Group sales growth accelerated to 9% (7% in CHF) in the second quarter as the decline in COVID-19-related sales no longer had an impact on overall salesPharmaceuticals Division sales rose by 5% in the first half; strong growth of 8% in the base business2 excluding COVID-19 effect
